nodes	percent_of_prediction	percent_of_DWPC	metapath
Ribavirin—Fludarabine—lymphatic system cancer	0.217	0.514	CrCtD
Ribavirin—Cytarabine—lymphatic system cancer	0.205	0.486	CrCtD
Ribavirin—SLC28A3—Fludarabine—lymphatic system cancer	0.12	0.472	CbGbCtD
Ribavirin—SLC29A1—Fludarabine—lymphatic system cancer	0.0795	0.314	CbGbCtD
Ribavirin—SLC29A1—Cytarabine—lymphatic system cancer	0.0543	0.214	CbGbCtD
Ribavirin—Glucosamine—Cytarabine—lymphatic system cancer	0.024	0.0851	CrCrCtD
Ribavirin—Regadenoson—Fludarabine—lymphatic system cancer	0.0165	0.0586	CrCrCtD
Ribavirin—S-Adenosylmethionine—Fludarabine—lymphatic system cancer	0.0165	0.0586	CrCrCtD
Ribavirin—Clofarabine—Fludarabine—lymphatic system cancer	0.0165	0.0586	CrCrCtD
Ribavirin—Regadenoson—Cytarabine—lymphatic system cancer	0.0156	0.0553	CrCrCtD
Ribavirin—S-Adenosylmethionine—Cytarabine—lymphatic system cancer	0.0156	0.0553	CrCrCtD
Ribavirin—Clofarabine—Cytarabine—lymphatic system cancer	0.0156	0.0553	CrCrCtD
Ribavirin—Fludarabine—Cytarabine—lymphatic system cancer	0.0146	0.0519	CrCrCtD
Ribavirin—Adenosine monophosphate—Fludarabine—lymphatic system cancer	0.0146	0.0518	CrCrCtD
Ribavirin—Nelarabine—Fludarabine—lymphatic system cancer	0.0146	0.0518	CrCrCtD
Ribavirin—Cytarabine—Fludarabine—lymphatic system cancer	0.0138	0.049	CrCrCtD
Ribavirin—Nelarabine—Cytarabine—lymphatic system cancer	0.0138	0.0489	CrCrCtD
Ribavirin—Adenosine monophosphate—Cytarabine—lymphatic system cancer	0.0138	0.0489	CrCrCtD
Ribavirin—Azacitidine—Fludarabine—lymphatic system cancer	0.0131	0.0465	CrCrCtD
Ribavirin—Vidarabine—Fludarabine—lymphatic system cancer	0.0131	0.0465	CrCrCtD
Ribavirin—Adenosine—Fludarabine—lymphatic system cancer	0.0131	0.0465	CrCrCtD
Ribavirin—Azacitidine—Cytarabine—lymphatic system cancer	0.0124	0.0439	CrCrCtD
Ribavirin—Adenosine—Cytarabine—lymphatic system cancer	0.0124	0.0439	CrCrCtD
Ribavirin—Vidarabine—Cytarabine—lymphatic system cancer	0.0124	0.0439	CrCrCtD
Ribavirin—Hypersensitivity—Fludarabine—lymphatic system cancer	4.01e-05	0.000935	CcSEcCtD
Ribavirin—Tremor—Carmustine—lymphatic system cancer	4e-05	0.000933	CcSEcCtD
Ribavirin—Anaphylactic shock—Bleomycin—lymphatic system cancer	3.99e-05	0.000931	CcSEcCtD
Ribavirin—Oedema—Bleomycin—lymphatic system cancer	3.99e-05	0.000931	CcSEcCtD
Ribavirin—Erythema—Mitoxantrone—lymphatic system cancer	3.97e-05	0.000925	CcSEcCtD
Ribavirin—Anaemia—Carmustine—lymphatic system cancer	3.94e-05	0.00092	CcSEcCtD
Ribavirin—Back pain—Vincristine—lymphatic system cancer	3.94e-05	0.000919	CcSEcCtD
Ribavirin—Vomiting—Teniposide—lymphatic system cancer	3.94e-05	0.000918	CcSEcCtD
Ribavirin—Sepsis—Methotrexate—lymphatic system cancer	3.92e-05	0.000915	CcSEcCtD
Ribavirin—Agitation—Carmustine—lymphatic system cancer	3.92e-05	0.000915	CcSEcCtD
Ribavirin—Thrombocytopenia—Bleomycin—lymphatic system cancer	3.91e-05	0.000911	CcSEcCtD
Ribavirin—Asthenia—Fludarabine—lymphatic system cancer	3.9e-05	0.000911	CcSEcCtD
Ribavirin—Rash—Teniposide—lymphatic system cancer	3.9e-05	0.000911	CcSEcCtD
Ribavirin—Dermatitis—Teniposide—lymphatic system cancer	3.9e-05	0.00091	CcSEcCtD
Ribavirin—Dysgeusia—Mitoxantrone—lymphatic system cancer	3.89e-05	0.000906	CcSEcCtD
Ribavirin—Headache—Teniposide—lymphatic system cancer	3.88e-05	0.000905	CcSEcCtD
Ribavirin—Pruritus—Fludarabine—lymphatic system cancer	3.85e-05	0.000898	CcSEcCtD
Ribavirin—Lymphadenopathy—Methotrexate—lymphatic system cancer	3.85e-05	0.000897	CcSEcCtD
Ribavirin—Back pain—Mitoxantrone—lymphatic system cancer	3.84e-05	0.000895	CcSEcCtD
Ribavirin—Leukopenia—Carmustine—lymphatic system cancer	3.82e-05	0.000891	CcSEcCtD
Ribavirin—Anorexia—Bleomycin—lymphatic system cancer	3.8e-05	0.000887	CcSEcCtD
Ribavirin—Diabetes mellitus—Methotrexate—lymphatic system cancer	3.77e-05	0.00088	CcSEcCtD
Ribavirin—Anaemia—Vincristine—lymphatic system cancer	3.77e-05	0.000878	CcSEcCtD
Ribavirin—Agitation—Vincristine—lymphatic system cancer	3.74e-05	0.000873	CcSEcCtD
Ribavirin—Vision blurred—Mitoxantrone—lymphatic system cancer	3.74e-05	0.000872	CcSEcCtD
Ribavirin—Polyuria—Methotrexate—lymphatic system cancer	3.74e-05	0.000872	CcSEcCtD
Ribavirin—Hypotension—Bleomycin—lymphatic system cancer	3.73e-05	0.00087	CcSEcCtD
Ribavirin—Diarrhoea—Fludarabine—lymphatic system cancer	3.72e-05	0.000869	CcSEcCtD
Ribavirin—Convulsion—Carmustine—lymphatic system cancer	3.7e-05	0.000863	CcSEcCtD
Ribavirin—Hypertension—Carmustine—lymphatic system cancer	3.68e-05	0.000859	CcSEcCtD
Ribavirin—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	3.68e-05	0.000859	CcSEcCtD
Ribavirin—Nausea—Teniposide—lymphatic system cancer	3.68e-05	0.000858	CcSEcCtD
Ribavirin—Anaemia—Mitoxantrone—lymphatic system cancer	3.67e-05	0.000855	CcSEcCtD
Ribavirin—Vertigo—Vincristine—lymphatic system cancer	3.66e-05	0.000854	CcSEcCtD
Ribavirin—Hepatic failure—Methotrexate—lymphatic system cancer	3.65e-05	0.000852	CcSEcCtD
Ribavirin—Leukopenia—Vincristine—lymphatic system cancer	3.65e-05	0.000851	CcSEcCtD
Ribavirin—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	3.64e-05	0.000848	CcSEcCtD
Ribavirin—Chest pain—Carmustine—lymphatic system cancer	3.63e-05	0.000848	CcSEcCtD
Ribavirin—Myalgia—Carmustine—lymphatic system cancer	3.63e-05	0.000848	CcSEcCtD
Ribavirin—Anxiety—Carmustine—lymphatic system cancer	3.62e-05	0.000845	CcSEcCtD
Ribavirin—Paraesthesia—Bleomycin—lymphatic system cancer	3.58e-05	0.000836	CcSEcCtD
Ribavirin—Malaise—Mitoxantrone—lymphatic system cancer	3.58e-05	0.000835	CcSEcCtD
Ribavirin—Dyspnoea—Bleomycin—lymphatic system cancer	3.56e-05	0.00083	CcSEcCtD
Ribavirin—Leukopenia—Mitoxantrone—lymphatic system cancer	3.55e-05	0.000828	CcSEcCtD
Ribavirin—Convulsion—Vincristine—lymphatic system cancer	3.53e-05	0.000823	CcSEcCtD
Ribavirin—Hypertension—Vincristine—lymphatic system cancer	3.52e-05	0.00082	CcSEcCtD
Ribavirin—Confusional state—Carmustine—lymphatic system cancer	3.51e-05	0.000819	CcSEcCtD
Ribavirin—Oedema—Carmustine—lymphatic system cancer	3.48e-05	0.000812	CcSEcCtD
Ribavirin—Decreased appetite—Bleomycin—lymphatic system cancer	3.47e-05	0.000809	CcSEcCtD
Ribavirin—Myalgia—Vincristine—lymphatic system cancer	3.47e-05	0.000809	CcSEcCtD
Ribavirin—Visual disturbance—Methotrexate—lymphatic system cancer	3.46e-05	0.000808	CcSEcCtD
Ribavirin—Cough—Mitoxantrone—lymphatic system cancer	3.46e-05	0.000808	CcSEcCtD
Ribavirin—Vomiting—Fludarabine—lymphatic system cancer	3.46e-05	0.000807	CcSEcCtD
Ribavirin—Convulsion—Mitoxantrone—lymphatic system cancer	3.44e-05	0.000802	CcSEcCtD
Ribavirin—Rash—Fludarabine—lymphatic system cancer	3.43e-05	0.0008	CcSEcCtD
Ribavirin—Dermatitis—Fludarabine—lymphatic system cancer	3.43e-05	0.0008	CcSEcCtD
Ribavirin—Hypertension—Mitoxantrone—lymphatic system cancer	3.43e-05	0.000799	CcSEcCtD
Ribavirin—Pain—Bleomycin—lymphatic system cancer	3.41e-05	0.000796	CcSEcCtD
Ribavirin—Thrombocytopenia—Carmustine—lymphatic system cancer	3.41e-05	0.000795	CcSEcCtD
Ribavirin—Headache—Fludarabine—lymphatic system cancer	3.41e-05	0.000795	CcSEcCtD
Ribavirin—Tachycardia—Carmustine—lymphatic system cancer	3.4e-05	0.000793	CcSEcCtD
Ribavirin—Arthralgia—Mitoxantrone—lymphatic system cancer	3.38e-05	0.000788	CcSEcCtD
Ribavirin—Myalgia—Mitoxantrone—lymphatic system cancer	3.38e-05	0.000788	CcSEcCtD
Ribavirin—Chest pain—Mitoxantrone—lymphatic system cancer	3.38e-05	0.000788	CcSEcCtD
Ribavirin—Anxiety—Mitoxantrone—lymphatic system cancer	3.37e-05	0.000785	CcSEcCtD
Ribavirin—Lethargy—Methotrexate—lymphatic system cancer	3.35e-05	0.000781	CcSEcCtD
Ribavirin—Discomfort—Mitoxantrone—lymphatic system cancer	3.34e-05	0.000778	CcSEcCtD
Ribavirin—Anaphylactic shock—Vincristine—lymphatic system cancer	3.32e-05	0.000776	CcSEcCtD
Ribavirin—Oedema—Vincristine—lymphatic system cancer	3.32e-05	0.000776	CcSEcCtD
Ribavirin—Anorexia—Carmustine—lymphatic system cancer	3.32e-05	0.000774	CcSEcCtD
Ribavirin—Feeling abnormal—Bleomycin—lymphatic system cancer	3.29e-05	0.000767	CcSEcCtD
Ribavirin—Confusional state—Mitoxantrone—lymphatic system cancer	3.26e-05	0.000762	CcSEcCtD
Ribavirin—Nervous system disorder—Vincristine—lymphatic system cancer	3.26e-05	0.000761	CcSEcCtD
Ribavirin—Thrombocytopenia—Vincristine—lymphatic system cancer	3.26e-05	0.000759	CcSEcCtD
Ribavirin—Hypotension—Carmustine—lymphatic system cancer	3.25e-05	0.000759	CcSEcCtD
Ribavirin—Oedema—Mitoxantrone—lymphatic system cancer	3.24e-05	0.000755	CcSEcCtD
Ribavirin—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	3.24e-05	0.000755	CcSEcCtD
Ribavirin—Nausea—Fludarabine—lymphatic system cancer	3.23e-05	0.000754	CcSEcCtD
Ribavirin—Hyperhidrosis—Vincristine—lymphatic system cancer	3.21e-05	0.00075	CcSEcCtD
Ribavirin—Shock—Mitoxantrone—lymphatic system cancer	3.19e-05	0.000743	CcSEcCtD
Ribavirin—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	3.17e-05	0.00074	CcSEcCtD
Ribavirin—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	3.17e-05	0.00074	CcSEcCtD
Ribavirin—Urticaria—Bleomycin—lymphatic system cancer	3.17e-05	0.000739	CcSEcCtD
Ribavirin—Anorexia—Vincristine—lymphatic system cancer	3.17e-05	0.000739	CcSEcCtD
Ribavirin—Tachycardia—Mitoxantrone—lymphatic system cancer	3.16e-05	0.000737	CcSEcCtD
Ribavirin—Body temperature increased—Bleomycin—lymphatic system cancer	3.15e-05	0.000736	CcSEcCtD
Ribavirin—Insomnia—Carmustine—lymphatic system cancer	3.15e-05	0.000735	CcSEcCtD
Ribavirin—Skin disorder—Mitoxantrone—lymphatic system cancer	3.15e-05	0.000734	CcSEcCtD
Ribavirin—Irritability—Methotrexate—lymphatic system cancer	3.13e-05	0.000731	CcSEcCtD
Ribavirin—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	3.13e-05	0.00073	CcSEcCtD
Ribavirin—Paraesthesia—Carmustine—lymphatic system cancer	3.13e-05	0.00073	CcSEcCtD
Ribavirin—Mood swings—Methotrexate—lymphatic system cancer	3.11e-05	0.000725	CcSEcCtD
Ribavirin—Hypotension—Vincristine—lymphatic system cancer	3.11e-05	0.000725	CcSEcCtD
Ribavirin—Dyspnoea—Carmustine—lymphatic system cancer	3.11e-05	0.000724	CcSEcCtD
Ribavirin—Somnolence—Carmustine—lymphatic system cancer	3.1e-05	0.000722	CcSEcCtD
Ribavirin—Anorexia—Mitoxantrone—lymphatic system cancer	3.09e-05	0.00072	CcSEcCtD
Ribavirin—Ataxia—Methotrexate—lymphatic system cancer	3.09e-05	0.00072	CcSEcCtD
Ribavirin—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	3.03e-05	0.000707	CcSEcCtD
Ribavirin—Decreased appetite—Carmustine—lymphatic system cancer	3.03e-05	0.000706	CcSEcCtD
Ribavirin—Hypotension—Mitoxantrone—lymphatic system cancer	3.03e-05	0.000706	CcSEcCtD
Ribavirin—Insomnia—Vincristine—lymphatic system cancer	3.01e-05	0.000701	CcSEcCtD
Ribavirin—Gastrointestinal disorder—Carmustine—lymphatic system cancer	3.01e-05	0.000701	CcSEcCtD
Ribavirin—Paraesthesia—Vincristine—lymphatic system cancer	2.99e-05	0.000696	CcSEcCtD
Ribavirin—Pain—Carmustine—lymphatic system cancer	2.98e-05	0.000695	CcSEcCtD
Ribavirin—Constipation—Carmustine—lymphatic system cancer	2.98e-05	0.000695	CcSEcCtD
Ribavirin—Breast disorder—Methotrexate—lymphatic system cancer	2.97e-05	0.000692	CcSEcCtD
Ribavirin—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	2.96e-05	0.000689	CcSEcCtD
Ribavirin—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	2.95e-05	0.000688	CcSEcCtD
Ribavirin—Hypersensitivity—Bleomycin—lymphatic system cancer	2.94e-05	0.000686	CcSEcCtD
Ribavirin—Paraesthesia—Mitoxantrone—lymphatic system cancer	2.91e-05	0.000678	CcSEcCtD
Ribavirin—Decreased appetite—Vincristine—lymphatic system cancer	2.89e-05	0.000674	CcSEcCtD
Ribavirin—Dyspnoea—Mitoxantrone—lymphatic system cancer	2.89e-05	0.000673	CcSEcCtD
Ribavirin—Somnolence—Mitoxantrone—lymphatic system cancer	2.88e-05	0.000671	CcSEcCtD
Ribavirin—Gastrointestinal disorder—Vincristine—lymphatic system cancer	2.87e-05	0.00067	CcSEcCtD
Ribavirin—Feeling abnormal—Carmustine—lymphatic system cancer	2.87e-05	0.00067	CcSEcCtD
Ribavirin—Fatigue—Vincristine—lymphatic system cancer	2.87e-05	0.000669	CcSEcCtD
Ribavirin—Asthenia—Bleomycin—lymphatic system cancer	2.86e-05	0.000668	CcSEcCtD
Ribavirin—Dyspepsia—Mitoxantrone—lymphatic system cancer	2.85e-05	0.000665	CcSEcCtD
Ribavirin—Gastrointestinal pain—Carmustine—lymphatic system cancer	2.85e-05	0.000664	CcSEcCtD
Ribavirin—Pain—Vincristine—lymphatic system cancer	2.84e-05	0.000663	CcSEcCtD
Ribavirin—Constipation—Vincristine—lymphatic system cancer	2.84e-05	0.000663	CcSEcCtD
Ribavirin—Asthma—Methotrexate—lymphatic system cancer	2.84e-05	0.000662	CcSEcCtD
Ribavirin—Pruritus—Bleomycin—lymphatic system cancer	2.82e-05	0.000659	CcSEcCtD
Ribavirin—Decreased appetite—Mitoxantrone—lymphatic system cancer	2.81e-05	0.000657	CcSEcCtD
Ribavirin—Fatigue—Mitoxantrone—lymphatic system cancer	2.79e-05	0.000651	CcSEcCtD
Ribavirin—Pancreatitis—Methotrexate—lymphatic system cancer	2.78e-05	0.000649	CcSEcCtD
Ribavirin—Constipation—Mitoxantrone—lymphatic system cancer	2.77e-05	0.000646	CcSEcCtD
Ribavirin—Pain—Mitoxantrone—lymphatic system cancer	2.77e-05	0.000646	CcSEcCtD
Ribavirin—Body temperature increased—Carmustine—lymphatic system cancer	2.75e-05	0.000642	CcSEcCtD
Ribavirin—Abdominal pain—Carmustine—lymphatic system cancer	2.75e-05	0.000642	CcSEcCtD
Ribavirin—Abdominal discomfort—Methotrexate—lymphatic system cancer	2.72e-05	0.000634	CcSEcCtD
Ribavirin—Gastrointestinal pain—Vincristine—lymphatic system cancer	2.72e-05	0.000634	CcSEcCtD
Ribavirin—Feeling abnormal—Mitoxantrone—lymphatic system cancer	2.67e-05	0.000622	CcSEcCtD
Ribavirin—Neutropenia—Methotrexate—lymphatic system cancer	2.65e-05	0.000619	CcSEcCtD
Ribavirin—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	2.65e-05	0.000618	CcSEcCtD
Ribavirin—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	2.64e-05	0.000615	CcSEcCtD
Ribavirin—Abdominal pain—Vincristine—lymphatic system cancer	2.63e-05	0.000613	CcSEcCtD
Ribavirin—Body temperature increased—Vincristine—lymphatic system cancer	2.63e-05	0.000613	CcSEcCtD
Ribavirin—Erectile dysfunction—Methotrexate—lymphatic system cancer	2.61e-05	0.000609	CcSEcCtD
Ribavirin—Photosensitivity reaction—Methotrexate—lymphatic system cancer	2.59e-05	0.000604	CcSEcCtD
Ribavirin—Urticaria—Mitoxantrone—lymphatic system cancer	2.57e-05	0.0006	CcSEcCtD
Ribavirin—Hypersensitivity—Carmustine—lymphatic system cancer	2.57e-05	0.000599	CcSEcCtD
Ribavirin—Abdominal pain—Mitoxantrone—lymphatic system cancer	2.56e-05	0.000597	CcSEcCtD
Ribavirin—Body temperature increased—Mitoxantrone—lymphatic system cancer	2.56e-05	0.000597	CcSEcCtD
Ribavirin—Pneumonia—Methotrexate—lymphatic system cancer	2.54e-05	0.000593	CcSEcCtD
Ribavirin—Vomiting—Bleomycin—lymphatic system cancer	2.54e-05	0.000592	CcSEcCtD
Ribavirin—Infestation NOS—Methotrexate—lymphatic system cancer	2.53e-05	0.00059	CcSEcCtD
Ribavirin—Infestation—Methotrexate—lymphatic system cancer	2.53e-05	0.00059	CcSEcCtD
Ribavirin—Depression—Methotrexate—lymphatic system cancer	2.52e-05	0.000588	CcSEcCtD
Ribavirin—Rash—Bleomycin—lymphatic system cancer	2.52e-05	0.000587	CcSEcCtD
Ribavirin—Dermatitis—Bleomycin—lymphatic system cancer	2.51e-05	0.000586	CcSEcCtD
Ribavirin—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	2.51e-05	0.000585	CcSEcCtD
Ribavirin—Asthenia—Carmustine—lymphatic system cancer	2.5e-05	0.000583	CcSEcCtD
Ribavirin—Renal failure—Methotrexate—lymphatic system cancer	2.49e-05	0.00058	CcSEcCtD
Ribavirin—Stomatitis—Methotrexate—lymphatic system cancer	2.47e-05	0.000575	CcSEcCtD
Ribavirin—Conjunctivitis—Methotrexate—lymphatic system cancer	2.46e-05	0.000574	CcSEcCtD
Ribavirin—Hypersensitivity—Vincristine—lymphatic system cancer	2.45e-05	0.000571	CcSEcCtD
Ribavirin—Hepatobiliary disease—Methotrexate—lymphatic system cancer	2.39e-05	0.000558	CcSEcCtD
Ribavirin—Epistaxis—Methotrexate—lymphatic system cancer	2.39e-05	0.000557	CcSEcCtD
Ribavirin—Hypersensitivity—Mitoxantrone—lymphatic system cancer	2.39e-05	0.000556	CcSEcCtD
Ribavirin—Asthenia—Vincristine—lymphatic system cancer	2.39e-05	0.000556	CcSEcCtD
Ribavirin—Diarrhoea—Carmustine—lymphatic system cancer	2.38e-05	0.000556	CcSEcCtD
Ribavirin—Nausea—Bleomycin—lymphatic system cancer	2.37e-05	0.000553	CcSEcCtD
Ribavirin—Asthenia—Mitoxantrone—lymphatic system cancer	2.32e-05	0.000542	CcSEcCtD
Ribavirin—Dizziness—Carmustine—lymphatic system cancer	2.3e-05	0.000537	CcSEcCtD
Ribavirin—Haemoglobin—Methotrexate—lymphatic system cancer	2.28e-05	0.000532	CcSEcCtD
Ribavirin—Diarrhoea—Vincristine—lymphatic system cancer	2.27e-05	0.000531	CcSEcCtD
Ribavirin—Haemorrhage—Methotrexate—lymphatic system cancer	2.27e-05	0.00053	CcSEcCtD
Ribavirin—Hepatitis—Methotrexate—lymphatic system cancer	2.27e-05	0.00053	CcSEcCtD
Ribavirin—Pharyngitis—Methotrexate—lymphatic system cancer	2.25e-05	0.000526	CcSEcCtD
Ribavirin—Urinary tract disorder—Methotrexate—lymphatic system cancer	2.24e-05	0.000523	CcSEcCtD
Ribavirin—Urethral disorder—Methotrexate—lymphatic system cancer	2.23e-05	0.000519	CcSEcCtD
Ribavirin—Diarrhoea—Mitoxantrone—lymphatic system cancer	2.22e-05	0.000517	CcSEcCtD
Ribavirin—Vomiting—Carmustine—lymphatic system cancer	2.21e-05	0.000517	CcSEcCtD
Ribavirin—Dizziness—Vincristine—lymphatic system cancer	2.2e-05	0.000513	CcSEcCtD
Ribavirin—Rash—Carmustine—lymphatic system cancer	2.2e-05	0.000512	CcSEcCtD
Ribavirin—Dermatitis—Carmustine—lymphatic system cancer	2.19e-05	0.000512	CcSEcCtD
Ribavirin—Visual impairment—Methotrexate—lymphatic system cancer	2.19e-05	0.00051	CcSEcCtD
Ribavirin—Headache—Carmustine—lymphatic system cancer	2.18e-05	0.000509	CcSEcCtD
Ribavirin—Erythema multiforme—Methotrexate—lymphatic system cancer	2.15e-05	0.000501	CcSEcCtD
Ribavirin—Eye disorder—Methotrexate—lymphatic system cancer	2.12e-05	0.000495	CcSEcCtD
Ribavirin—Tinnitus—Methotrexate—lymphatic system cancer	2.12e-05	0.000494	CcSEcCtD
Ribavirin—Vomiting—Vincristine—lymphatic system cancer	2.11e-05	0.000493	CcSEcCtD
Ribavirin—Cardiac disorder—Methotrexate—lymphatic system cancer	2.11e-05	0.000492	CcSEcCtD
Ribavirin—Rash—Vincristine—lymphatic system cancer	2.1e-05	0.000489	CcSEcCtD
Ribavirin—Dermatitis—Vincristine—lymphatic system cancer	2.09e-05	0.000489	CcSEcCtD
Ribavirin—Headache—Vincristine—lymphatic system cancer	2.08e-05	0.000486	CcSEcCtD
Ribavirin—Nausea—Carmustine—lymphatic system cancer	2.07e-05	0.000483	CcSEcCtD
Ribavirin—Angiopathy—Methotrexate—lymphatic system cancer	2.06e-05	0.000481	CcSEcCtD
Ribavirin—Vomiting—Mitoxantrone—lymphatic system cancer	2.06e-05	0.00048	CcSEcCtD
Ribavirin—Immune system disorder—Methotrexate—lymphatic system cancer	2.05e-05	0.000478	CcSEcCtD
Ribavirin—Mediastinal disorder—Methotrexate—lymphatic system cancer	2.05e-05	0.000477	CcSEcCtD
Ribavirin—Rash—Mitoxantrone—lymphatic system cancer	2.04e-05	0.000476	CcSEcCtD
Ribavirin—Dermatitis—Mitoxantrone—lymphatic system cancer	2.04e-05	0.000476	CcSEcCtD
Ribavirin—Chills—Methotrexate—lymphatic system cancer	2.04e-05	0.000475	CcSEcCtD
Ribavirin—Headache—Mitoxantrone—lymphatic system cancer	2.03e-05	0.000473	CcSEcCtD
Ribavirin—Alopecia—Methotrexate—lymphatic system cancer	2.01e-05	0.000468	CcSEcCtD
Ribavirin—Mental disorder—Methotrexate—lymphatic system cancer	1.99e-05	0.000464	CcSEcCtD
Ribavirin—Malnutrition—Methotrexate—lymphatic system cancer	1.98e-05	0.000461	CcSEcCtD
Ribavirin—Erythema—Methotrexate—lymphatic system cancer	1.98e-05	0.000461	CcSEcCtD
Ribavirin—Nausea—Vincristine—lymphatic system cancer	1.97e-05	0.000461	CcSEcCtD
Ribavirin—Dysgeusia—Methotrexate—lymphatic system cancer	1.94e-05	0.000452	CcSEcCtD
Ribavirin—Nausea—Mitoxantrone—lymphatic system cancer	1.92e-05	0.000449	CcSEcCtD
Ribavirin—Back pain—Methotrexate—lymphatic system cancer	1.91e-05	0.000446	CcSEcCtD
Ribavirin—Vision blurred—Methotrexate—lymphatic system cancer	1.86e-05	0.000435	CcSEcCtD
Ribavirin—Ill-defined disorder—Methotrexate—lymphatic system cancer	1.83e-05	0.000428	CcSEcCtD
Ribavirin—Anaemia—Methotrexate—lymphatic system cancer	1.83e-05	0.000426	CcSEcCtD
Ribavirin—Malaise—Methotrexate—lymphatic system cancer	1.78e-05	0.000416	CcSEcCtD
Ribavirin—Vertigo—Methotrexate—lymphatic system cancer	1.78e-05	0.000414	CcSEcCtD
Ribavirin—Leukopenia—Methotrexate—lymphatic system cancer	1.77e-05	0.000413	CcSEcCtD
Ribavirin—Cough—Methotrexate—lymphatic system cancer	1.72e-05	0.000402	CcSEcCtD
Ribavirin—Convulsion—Methotrexate—lymphatic system cancer	1.71e-05	0.0004	CcSEcCtD
Ribavirin—Chest pain—Methotrexate—lymphatic system cancer	1.68e-05	0.000393	CcSEcCtD
Ribavirin—Myalgia—Methotrexate—lymphatic system cancer	1.68e-05	0.000393	CcSEcCtD
Ribavirin—Arthralgia—Methotrexate—lymphatic system cancer	1.68e-05	0.000393	CcSEcCtD
Ribavirin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	1.67e-05	0.00039	CcSEcCtD
Ribavirin—Discomfort—Methotrexate—lymphatic system cancer	1.66e-05	0.000388	CcSEcCtD
Ribavirin—Confusional state—Methotrexate—lymphatic system cancer	1.63e-05	0.000379	CcSEcCtD
Ribavirin—Anaphylactic shock—Methotrexate—lymphatic system cancer	1.61e-05	0.000376	CcSEcCtD
Ribavirin—Nervous system disorder—Methotrexate—lymphatic system cancer	1.58e-05	0.000369	CcSEcCtD
Ribavirin—Thrombocytopenia—Methotrexate—lymphatic system cancer	1.58e-05	0.000368	CcSEcCtD
Ribavirin—Skin disorder—Methotrexate—lymphatic system cancer	1.57e-05	0.000366	CcSEcCtD
Ribavirin—Hyperhidrosis—Methotrexate—lymphatic system cancer	1.56e-05	0.000364	CcSEcCtD
Ribavirin—Anorexia—Methotrexate—lymphatic system cancer	1.54e-05	0.000359	CcSEcCtD
Ribavirin—Hypotension—Methotrexate—lymphatic system cancer	1.51e-05	0.000352	CcSEcCtD
Ribavirin—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	1.47e-05	0.000343	CcSEcCtD
Ribavirin—Insomnia—Methotrexate—lymphatic system cancer	1.46e-05	0.00034	CcSEcCtD
Ribavirin—Paraesthesia—Methotrexate—lymphatic system cancer	1.45e-05	0.000338	CcSEcCtD
Ribavirin—Dyspnoea—Methotrexate—lymphatic system cancer	1.44e-05	0.000336	CcSEcCtD
Ribavirin—Somnolence—Methotrexate—lymphatic system cancer	1.43e-05	0.000335	CcSEcCtD
Ribavirin—Dyspepsia—Methotrexate—lymphatic system cancer	1.42e-05	0.000331	CcSEcCtD
Ribavirin—Decreased appetite—Methotrexate—lymphatic system cancer	1.4e-05	0.000327	CcSEcCtD
Ribavirin—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	1.39e-05	0.000325	CcSEcCtD
Ribavirin—Fatigue—Methotrexate—lymphatic system cancer	1.39e-05	0.000324	CcSEcCtD
Ribavirin—Pain—Methotrexate—lymphatic system cancer	1.38e-05	0.000322	CcSEcCtD
Ribavirin—Feeling abnormal—Methotrexate—lymphatic system cancer	1.33e-05	0.00031	CcSEcCtD
Ribavirin—Gastrointestinal pain—Methotrexate—lymphatic system cancer	1.32e-05	0.000308	CcSEcCtD
Ribavirin—Urticaria—Methotrexate—lymphatic system cancer	1.28e-05	0.000299	CcSEcCtD
Ribavirin—Abdominal pain—Methotrexate—lymphatic system cancer	1.28e-05	0.000297	CcSEcCtD
Ribavirin—Body temperature increased—Methotrexate—lymphatic system cancer	1.28e-05	0.000297	CcSEcCtD
Ribavirin—Hypersensitivity—Methotrexate—lymphatic system cancer	1.19e-05	0.000277	CcSEcCtD
Ribavirin—Asthenia—Methotrexate—lymphatic system cancer	1.16e-05	0.00027	CcSEcCtD
Ribavirin—Pruritus—Methotrexate—lymphatic system cancer	1.14e-05	0.000266	CcSEcCtD
Ribavirin—Diarrhoea—Methotrexate—lymphatic system cancer	1.1e-05	0.000257	CcSEcCtD
Ribavirin—Dizziness—Methotrexate—lymphatic system cancer	1.07e-05	0.000249	CcSEcCtD
Ribavirin—Vomiting—Methotrexate—lymphatic system cancer	1.03e-05	0.000239	CcSEcCtD
Ribavirin—Rash—Methotrexate—lymphatic system cancer	1.02e-05	0.000237	CcSEcCtD
Ribavirin—Dermatitis—Methotrexate—lymphatic system cancer	1.02e-05	0.000237	CcSEcCtD
Ribavirin—Headache—Methotrexate—lymphatic system cancer	1.01e-05	0.000236	CcSEcCtD
Ribavirin—Nausea—Methotrexate—lymphatic system cancer	9.58e-06	0.000224	CcSEcCtD
